Table 3.
O3FA effects on PPF, LFN, FW, FCRL, and CLN
| Mated groups | PPF (%) | LFN | FW (g) | FCRL (cm) | CLN |
|---|---|---|---|---|---|
| 1 | 100 | 8.67 ± 0.33b | 4.97 ± 0.25abc | 4.41 ± 0.15c | 9.17 ± 0.40d |
| 2 | 100 | 9.00 ± 0.26b | 6.05 ± 0.21c | 4.21 ± 0.09bc | 10.00 ± 0.37d |
| 3 | 100 | 7.83 ± 0.48b | 5.09 ± 0.18abc | 4.34 ± 0.34c | 8.33 ± 0.42cd |
| 4 | 100 | 8.00 ± 0.45b | 5.75 ± 0.21bc | 4.68 ± 0.03c | 9.00 ± 0.37cd |
| 5 | 67 | 2.83 ± 0.90a | 3.76 ± 1.19ab | 2.76 ± 0.87ab | 3.83 ± 1.32ab |
| 6 | 50 | 3.17 ± 1.56a | 2.96 ± 1.32a | 2.04 ± 0.91a | 3.50 ± 1.75a |
| 7 | 100 | 5.17 ± 0.65a | 5.68 ± 0.13bc | 4.08 ± 004bc | 6.33 ± 0.42bc |
Values with different alphabet superscript in a column were significantly different (P<0.05). Data for LFN, FW, FCRL, and CLN are presented as mean±SE. O3FA: Omega-3 fatty acids, PPF: Percentage of pregnant females, LFN: Life foetal number, FW: Foetal weight, FCRL: Foetal crown-rump length, and CLN: Corpora luteal number. Mated groups: 1 = Placebo (control) female mated with placebo (control) male, 2 = O3FA female mated with placebo male, 3 = Placebo female mated with O3FA male, 4 = O3FA female mated with O3FA male, 5 = CPP female mated with placebo male, 6 = Placebo female mated with CPP male, and 7 = CPP + O3FA female mated with CPP + O3FA male